SAB Biotherapeutics Swings to Q3 Net Loss of $22.3 Million

Bitget2026/11/05 12:42

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SAB Biotherapeutics swung to a Q3 2026 net loss of $22.3 million from year-earlier net income of $45.4 million.
Research and development expenses more than doubled to $18.1 million; general and administrative expenses more than doubled to $7.8 million.
Cash, cash equivalents and investment securities totaled $205.3 million at September 30, providing operational runway through 2028.
SAFEGUARD enrollment remains on track for completion in Q4 2026, with topline data expected in the second half of 2027.
SAB-142 received FDA Fast Track designation in October 2026 for treatment of new-onset Stage 3 type 1 diabetes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050730PRIMZONEFULLFEED9870502) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03